Autoregulation of 5-fluorouracil metabolism-Reference-Cited by-同舟云学术

Autoregulation of 5-fluorouracil metabolism

Published:1998-09 Issue:10 Volume:34 Page:1623-1627
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

McLeod H.L.,Sludden J.,Hardy S.C.,Lock R.E.,Hawksworth G.M.,Cassidy J.

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference34 articles.

1. Diagnostic analysis, clinical importance and molecular basis of dihydropyrimidine dehydrogenase;Gonzalez;Trends Pharmacol Sci,1995

2. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile;Heggie;Cancer Res,1987

3. Clinical pharmacology of 5-fluorouracil;Diasio;Clin Pharmacokinet,1989

4. A comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cell in patients with colorectal cancer;Wattanatorn;Pharmacotherapy,1997

5. Milano G, Etienne MC, Renee N, et al. Relationship between fluorouracil systemic exposure and tumor response and patient survival. J Clin Oncol 1994, 12, 1291–1295.

Cited by 37 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Conflicting alterations in hepatic expression of CYP3A and enzyme kinetics in rats exposed to 5-fluorouracil: relevance to pharmacokinetics of midazolam;Xenobiotica;2019-03-05

2. Combinatorial Measurement of CDKN1A/p21 and KIF20A Expression for Discrimination of DNA Damage-Induced Clastogenicity;International Journal of Molecular Sciences;2014-09-26

3. Predicting 5-fluorouracil toxicity: DPD genotype and 5,6-dihydrouracil:uracil ratio;Pharmacogenomics;2014-09

4. Personalized Dosing via Pharmacokinetic Monitoring of 5-Fluorouracil Might Reduce Toxicity in Early- or Late-Stage Colorectal Cancer Patients Treated With Infusional 5–Fluorouracil-Based Chemotherapy Regimens;Clinical Colorectal Cancer;2014-06

5. Utilization of CDKN1A/p21 gene for class discrimination of DNA damage-induced clastogenicity;Toxicology;2014-01